Price: $12.73
· 1 day: -3.63% · 5 days: +11.57% · 1 month: +25.54% · YTD: -30.21%
As of 2026-11-06 21:00 UTC.
52-week range: $7.21 – $20.46 (currently at 42% of the range).
ADMA is in an uptrend, momentum firm. $13 is the level overhead; $12 the first support below.
5 of 6 technical checks lean bullish.
| Trend | Uptrend · above 50-day & 200-day |
|---|---|
| Momentum | RSI 63.05 · neutral · MACD bullish |
| Trend strength | ADX 27.9 · strong trend |
| Location | +24.7% vs 50-day MA |
| 52-week range | -38% from high · +68% from low |
| Volatility | ATR 0.7 · ~5.5%/day |
| Level | Type | Distance |
|---|---|---|
| $13.0 (resistance) | round | 2.12% |
| $14.0 (resistance) | round | 9.98% |
| $20.38 (resistance) | 52w high | 60.09% |
| $12.0 (support) | round | -5.73% |
| $11.37 (support) | swing zone | -10.68% |
| $11.0 (support) | round | -13.59% |
| RSI (14) | 63.05 | MACD | 0.5287 |
|---|---|---|---|
| ADX (14) | 27.9 | ATR (14) | 0.7 |
| 50-day average | $10.21 | 200-day average | $10.82 |
Next earnings: 2026-11-04. ADMA earnings date, time and past reactions.
Report of 2026-10-28, updated 2026-11-05.
ADMA Biologics (ADMA) has surged 25.4% on November 5, 2026, following its Q3 earnings report on November 4, which showed revenue of $141.1 million (+5% YoY) and net income of $49.9 million (+37% YoY), with ASCENIV revenue up 31% YoY (SEC EDGAR). Over the past five days, the stock is up 11.9%, while the S&P 500 is down 2.8% and XLV is up 3.7%, reinforcing its leadership. The stock has reclaimed its 200-day average and now trades at $13.145, above the 13.0 round support level from the prior report.
The picture holds. The bullish stance with high conviction remains intact, as the stock continues to lead both the market and sector over 50 days (+32.9% vs SPY, +17.8% vs XLV). The breakout level of 14.0 (round) is now closer, with resistance at 14.0, 15.0, and the 52-week high of 20.38. Support has moved up: the 200-day average at 10.84 is now well below price, and the 50-day average at 10.14 is further down. The stop at 12.84 (13.0 minus a quarter of ATR) remains relevant, and a daily close above 14.0 on volume above the 20-day average would trigger the upside breakout. What would change the picture is a weekly close below the 200-day average at 10.84.
ADMA Biologics (ADMA) trades at $11.17, and the balance of evidence now leans positive for the next 2–6 weeks, a reversal from the bearish reading of October 16, 2026. The stock has moved above its 40-week average, leads both the S&P 500 and the healthcare sector over 50 days, and sits just under the $11.37 level that would confirm a breakout. Conviction is high, with earnings due November 4.
The only recent news item is not an ADMA event. On September 22, 2026 Kedrion Biopharma announced that the FDA had granted Orphan Drug Designation to its immunoglobulin product QIVIGY for Stiff Person Syndrome, PR Newswire reported. It is a competitor's regulatory step in a rare-disease niche, a month old, and it does not explain the recent move in ADMA. The stock's advance has no identifiable headline behind it, and that matters for how much weight it can carry.
The move itself is modest over the last week and larger over the last month. ADMA is up 1.5% over five days, against a 0.4% fall for the S&P 500 and a 0.6% gain for the healthcare sector (XLV). The stock therefore beat its sector by about 0.9 percentage points, and the market was no help. Over one month ADMA is up 10.4%, against 0.6% for the S&P 500 and 5.1% for XLV. Over 50 days it leads the S&P 500 by 12.1 points and XLV by 7.4 points. This is mostly the stock's own strength, with the sector contributing a smaller part.
The longer record is less flattering. ADMA is still down 38.8% year to date while the S&P 500 is up 13.0% and XLV is up 16.3%. Against the S&P 500 it still trails by 5.4 points over 200 days. The shares are 45.2% below their 52-week high of $20.38 and 47.0% above the low of $7.60. The recent rally is a recovery inside a much larger drawdown, not a return to old highs.
No articles making a case for or against ADMA were available for this report, so the debate has to be taken from the numbers. Four analysts cover the stock and none carries a consensus rating. Their price targets run from $12 to $21 with a mean of $17, which puts the shares 34.3% below the mean. Even the lowest target is above today's price. That spread is wide, and it shows how far the analysts' view of the company's earning power sits from what the market is paying for a $2.5 billion biotech.
On the long term, the thesis has gone from broken to repaired but unproven. On October 16, 2026 the earlier report called the stance bearish with low conviction, because price was below its 40-week average and the daily trend was only a pullback within a downtrend. That reading rested on a weekly close above $11.31, the 200-day average at the time, as the point that would change it. Since then the 200-day average has eased to $11.02, and price has moved above it and above the 40-week average. The weekly trend is up, and the stock is in the early phase of a recovery from a deep decline, not in a mature uptrend.
For the next 2–6 weeks the evidence leans positive, with high conviction of 3 of 4 points. The daily trend runs with the weekly uptrend, and ADMA leads both the S&P 500 and XLV over 50 days. That agreement is why the stance changed from the earlier report. Trend and relative strength both point the same way now, and in October 16 they did not.
The strongest case against it is that the breakout has not happened. The stock closed at $11.23 on October 20, 2026, and it now trades 0.5% below that peak, still under the $11.37 resistance. The 14-day RSI is 67.5, close to overbought territory, and volume in the session so far is far below its 20-day average, though the day is young. Earnings on November 4 can overwhelm any chart. These points are why conviction is not at the maximum, but they do not outweigh a trend and relative-strength picture that agree.
The structure holds above $11.02, the 200-day average. That is the first place a crack would show, and the price is only slightly above it. Below it the trend ends at $9.93, the 50-day average, close to the $10.00 round number and the next support zones at $9.26 and $8.20. Those levels matter because they are where buyers have defended the stock before, and the 200-day and 50-day averages are the lines most holders of the stock watch.
The breakout level is a daily close above $11.37 on volume above its 20-day average. From there, resistance sits at $12.00 and $13.00, and the 52-week high of $20.38 is the target in the math. The stop is $10.93, which is the 200-day average at $11.02 minus a quarter of the 14-day ATR of $0.34. Against that stop the reward-to-risk to $20.38 is 20.5 to 1, well past the 3 to 1 that makes a breakout worth the risk. That ratio is large mainly because the stop is so tight, and the target is a long way off. A close below $10.93 would mean the breakout failed.
A weekly close below $9.93, the 50-day average, would change the picture, because it would end the weekly trend that the current reading rests on. The non-price fact that could do it is the earnings report on November 4: results or guidance that disappoint, in a stock that has risen without a news catalyst, could take the price through the $11.02 and $10.00 levels on the way down.
Interactive ADMA chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs